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E-mail address: abutte@stanford.edu (A.J. Butte).Bioinformatics methods that leverage the vast amounts of clinical data promises to provide insights into
underlying molecular mechanisms that help explain human physiological processes. One of these pro-
cesses is adolescent development. The utility of predictive aging models generated from cross-sectional
cohorts and their applicability to separate populations, including the clinical population, has yet to be
completely explored. In order to address this, we built regression models predictive of adolescent chro-
nological age from 2001 to 2002 National Health and Nutrition Examination Survey (NHANES) data and
validated them against independent 2003–2004 NHANES data and clinical data from an academic ter-
tiary-care pediatric hospital. The results indicate distinct differences between male and female models
with both alkaline phosphatase and creatinine as predictive biomarkers for both genders, hematocrit
and mean cell volume for males, and total serum globulin for females. We also suggest that the models
are generalizable, are clinically relevant, and imply underlying molecular and clinical differences
between males and females that may affect prediction accuracy. The integration of both epidemiological
and clinical data promises to create more robust models that shed new light on physiological processes.
 2009 Elsevier Inc. All rights reserved.1. Introduction
Methodological innovation that uses data from basic biology
and translates it for clinical relevance has often been the crux of
translational bioinformatics. It is less often that we use data col-
lected in the clinical environment to gain a better understanding
of the biological underpinnings of human physiological processes
or to validate hypotheses that may be generated in the traditional
manner. Although the majority of research surrounding clinical
data deals with acquisition of data, in the form of electronic med-
ical records [1], and the application of this data to improve patient
care [2], the data collected inherently has the ability to shed light
on novel biology [3]. Clinical measurements are a window into
underlying molecular processes that change accordingly with the
physiological characteristics of the individual, whether it is gender,
age, disease status, or one of the countless states that an individual
can take.
The term reverse translational bioinformatics has been coined
recently to describe the use of clinically relevant data to gain in-
sight into basic biological phenomena [4]. Fliss and colleaguesll rights reserved.
edical Informatics Research,
l of Medicine, 251 Campus
A. Fax: +1 650 723 7070.show that the use of cross-sectional survey data in the form of
the 3rd National Health and Nutrition Examination Survey can be
used to study the interplay between age, gender, and blood bio-
markers. While they were able to show differentiated clusters of
individuals based upon age and gender, the applicability of models
built on one data set to other data sets, including data from clinical
electronic medical records, remains unknown. In this study we
examine the applicability of model building to various data
sources, including clinical data from an academic tertiary-care
pediatric hospital, in the context of pediatric development and
aging.
Well known markers for aging in the pediatric population in-
clude anthropometric measurements such as the comparison be-
tween individuals and landmarks on the human growth curve,
examining secondary sexual characteristics [5–7], dental develop-
ment [8–10], and skeletal development [11,12]. In fact, chronolog-
ical age can be estimated from these markers. The average error
between the estimated age and the actual chronological age has
been show to range from 0.32 years to 0.36 years for skeletal
development [13] and 1.18 years to 0.72 years for dental devel-
opment [14]. Moreover, these methods, some of which have been
used for almost half a century, are the standard of care when diag-
nosing individuals with developmental disorders. These anthropo-
metric measures are well known and commonly used, but are
markers for secondary changes and not primary aging.
Fig. 1. Schematic of the model building and prediction pipeline.
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dominantly in animal models. For instance, it has been shown that
maximum lifespan can be extended due to caloric restriction in
organisms including yeast, worms, ﬂies, and rodents [15–17].
While caloric restriction has been implicated in reducing the rate
of age-associated muscle loss in monkeys [18], its true effect in
increasing the maximum age of primates and humans is still un-
known. This is due to factors including malnutrition, which may
be associated with caloric restriction [19], and the difﬁculty of
studying aging in longer lived species. The release of sex steroids
via the hypothalamic–pituitary–gonadal axis and its affect in the
fetus, childhood, and pubertal phases has been studied for decades
[20,21]. More recently, mutations found in gonadotropins suggest
the clinical consequences of aberrant or delayed sexual differenti-
ation and development [22]. Other primary effectors of aging in-
clude IGF-1 and IGFBP-3 which have patterns of change
throughout childhood as a function of both age and pubertal stage
[23–25]. It has also been shown that IGF-1 and IGFBP-3 have a po-
sitive relationship with bone remodeling levels as indicated by ser-
um levels of bone alkaline phosphatase and CrossLaps [26].
However, there may be other physiological changes in early aging
beyond what we observe (primary and secondary sex characteris-
tics), sex steroid levels, height, and other anthropometric changes.
We propose the use of a broad panel of physiological measure-
ments obtained for cross-sectional research to discover biomarkers
that can correlate with age and development. Gender-speciﬁc mul-
tivariate linear regression models predicting adolescent chronolog-
ical age are built from 2001 to 2002 National Health and Nutrition
Examination Survey (NHANES) data. Models are then validated
against independent 2003–2004 NHANES data, as well as clinical
data from an academic tertiary-care pediatric hospital. A linear
regression using alkaline phosphatase, creatinine, hematocrit,
and mean cell volume was found to be predictive of male chrono-
logical age while a model built on alkaline phosphatase, creatinine,
and total serum globulin was found to be predictive in the female
population. We also suggest that models built from one data
source are applicable to independent cohorts implying the greater
role for clinical data in translational biomedical informatics.
2. Methods and results
The objective of this study was to gain insight into the primary
process of aging in the pediatric population by generating a multi-
variate linear model that uses non-radiographic biomarker mea-
surements (complete blood count and blood biochemistry
proﬁles) to predict pediatric age. We also wanted to determine
whether the models generated were applicable to data collected
from the clinical environment, speciﬁcally patients seen at Lucile
Packard Children’s Hospital (LPCH) and its outpatient clinics
(Fig. 1).
2.1. Model building using NHANES
NHANES is a biannual nationally representative cross sectional
health survey of the non-institutionalized population of the United
States conducted by the Centers for Disease Control and Prevention
[27]. Due to the lack of blood biochemistry proﬁles for respondents
less than 12 years of age, we limited our analysis to individuals be-
tween 12 and 18 years of age. Respondent data whose age at the
mobile examination center (MEC) examination date was within
this range were aggregated and joined by unique identiﬁers. Bio-
marker measurements were extracted from the Complete Blood
Count with 5-part Differential and the Standard Biochemistry Proﬁle,
Follicle Stimulating Hormone, and Luteinizing Hormone data tables.Duplicate biomarker measurements due to unit transformations
were removed. Luteinizing hormone and follicle stimulating hor-
mone were removed due to lack of coverage (50%), reﬂective of
their rare usage in pediatric care.
In total, NHANES 2001–2002 contained 1831 individuals aged
between 12 and 18 years with complete blood count and blood
biochemistry data. Thirty nine biomarkers were examined (Ta-
ble 1). Due to the large number of potential biomarkers, it was
desirable to reduce the number of parameters for the model. While
there are many methods that allow for the selection of a parsimo-
nious set of features for prediction of the response variable, we
chose Least Angle Regression (LARS) [28]. LARS is a computation-
ally efﬁcient method for model selection akin to forward selection.
The end result of applying this method is an ordered list of covar-
iates to include in the model. The beneﬁt is that this allows for the
most informative biomarkers to be chosen, which tend to be inde-
pendent of one another. Secondly, having less biomarkers neces-
sary for prediction potentially translates to fewer tests done in
the clinical setting. Individuals with any missing data were ex-
cluded leaving 1653 with complete data: 793 males and 860 fe-
males. Ninety percent of the individuals in both groups were
randomly sampled and used for model building (n = 744 females,
713 males).
Feature selection using LARS with 10-fold cross validation was
applied to each subgroup. Ranks of each biomarker were re-
corded along with the root mean squared error (RMSE) incurred
by the addition of each feature. After observing the RMSE trend
across the 10-fold validation sets, the male subgroup exhibited
four features before the RMSE leveled off while the female sub-
group exhibited three features (Fig. 2). The four biomarkers used
in the male model were alkaline phosphatase, creatinine, hemato-
crit and mean cell volume. The three biomarkers used in the fe-
male model were alkaline phosphatase, creatinine, and total
serum globulin. Upon further examination of the biomarkers used
in our models, we noticed that alkaline phosphatase had a non-
linear relationship with age. Due to its exponentially decreasing
nature we used a natural logarithm transformation of alkaline
phosphatase. The other biomarkers had a linear trend in the
age range of interest. A multivariate linear model was built for
each gender subgroup independently using their respective
features:
AgeMale ¼ 17:4679þ ð1:3705 ln ðAlkaline PhosphataseÞÞ
þ ð2:86545 CreatinineÞ þ ð0:0624HematocritÞ
þ ð0:01625Mean Cell VolumeÞ
Table 1
Top 10 most informative biomarkers along with Pearson’s correlation coefﬁcient between biomarker and age (r), p-value of the correlation with the null-hypothesis that there is
no linear association (r is equal to 0), and average least angle regression rank with 10-fold cross validation. Left: male, right: female. ALK, alkaline phosphatase (U/L); AST,
aspartamine aminotransferase (U/L); BIC, bicarbonate (mmol/L); BILI, bilirubin (mg/dL); CA, total calcium (mg/dL); CHOL, cholesterol (mg/dL); CR, creatinine (mg/dL); FE, iron (ug/
dL); GGT, gamma-glutamyl transpeptidase (U/L); GLOB, total serum globulin(g/dL); HCT, hematocrit (%); K, potassium (mmol/L); MCV, mean cell volume (fL); SNP, segmented
neutrophils percent (%); URIC, uric acid (mg/dL).
Male Female
Biomarker r p-value Average LARS rank Biomarker r p-value Average LARS rank
ALK 0.6659 <0.0001 1 ALK 0.6637 <0.0001 1
CR 0.6367 <0.0001 2 CR 0.3483 <0.0001 2
HCT 0.4809 <0.0001 3 GLOB 0.1451 0.0001 3.1
MCV 0.3385 <0.0001 5.9 CHOL 0.0683 0.0575 5
CA 0.0768 0.0404 6.1 SNP 0.174 <0.0001 6
URIC 0.3127 <0.0001 6.8 URIC 0.0558 0.1206 6.3
BILI 0.2131 <0.0001 6.9 GGT 0.067 0.0625 7.2
BIC 0.2514 <0.0001 7.3 FE 0.0547 0.1281 8.3
GGT 0.1674 <0.0001 7.9 CA 0.1529 <0.0001 10.4
AST 0.1293 0.0005 11.4 K 0.1044 0.0036 11.7
Fig. 2. Root mean squared error plots with conﬁdence intervals in relation to the number of features chosen, 0 indicates random. Left: female, right: male.
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þ ð1:4435 CreatinineÞ þ ð0:4122
 Total Serum GlobulinÞ
The models were ﬁrst used to determine the r2, residual stan-
dard error, and p-value when applied to the training data. The
null-hypothesis in a multivariate linear regression is that all of
the partial regression coefﬁcients are equal to 0 which can be
tested via an analysis of variance. The male subgroup model (ad-
justed r2 = 0.6301, residual standard error = 1.062, p-va-
lue < 0.0001) and female subgroup model (adjusted r2 = 0.5274,
residual standard error = 1.195, p-value < 0.0001) were then used
to predict age from the remaining 10% of the NHANES 2001–
2002 data (Fig. 3a). The female population (n = 86) resulted in a
mean error (difference between predicted age and expected age)
of 0.0978 years with a standard deviation of 1.2648 years and an
adjusted r2 of 0.5008. The male population (n = 80) resulted in a
mean error of 0.0308 years with a standard deviation of
0.9617 years and an adjusted r2 of 0.6667 (Table 2a).2.2. Model evaluation
We evaluated the accuracy of the model by checking its perfor-
mance on an independent yet similar set of subjects reﬂected inthe NHANES 2003–2004 data set. The above multivariate model
was applied to predict pediatric age. The female population
(n = 712) resulted in a mean error of 0.0667 years with a standard
deviation of 1.2241 years and an adjusted r2 of 0.5027. The male
population (n = 787) resulted in a mean error of 0.0699 years with
a standard deviation of 1.0768 years and an adjusted r2 of 0.6042
(Fig. 3b and Table 2b). These similar results suggest that our model
is applicable to independent NHANES data sets.2.3. Model validation on clinical samples
To assess how our models would perform on clinical data, de-
identiﬁed biomarker measurements and diagnosis codes linked
by synthetic patient identiﬁers from LPCH, both labeled with the
age in days of each patient, were used. LPCH laboratory test and
diagnosis data were retrieved via the Stanford Translational Re-
search Integrated Database Environment (STRIDE). The use of de-
identiﬁed individual data in this manner was approved by the
Institutional Review Board of the Stanford University School of
Medicine. Data for clinical biomarkers equivalent to those our
models required were extracted. Individuals were excluded if they
were diagnosed with any one of 23 ICD-9-CM codes that were di-
rectly related to developmental disorders (e.g. 259.0 or Delay in
sexual development and puberty not elsewhere classiﬁed) within
Fig. 3. Actual age versus predicted age for the three data sets with the 95% conﬁdence interval for the regression line: (a) NHANES 2001–2002 untrained, (b) NHANES 2003–
2004 and (c) LPCH.
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Table 2
Mean error, standard error, standard deviation, root mean squared error of the differences between predicted and expected chronological age, adjusted r2, and p-values for the
correlation between predicted and expected ages for: (a) NHANES 2001–2002, 10% untrained (b) NHANES 2003–2004, and (c) LPCH.
Gender Mean error (years) SE (years) SD (years) RMSE (years) Adjusted r2 p-value
(a) NHANES 2001–2002 (10% untrained)
Female (n = 86) 0.0978 0.1364 1.2648 1.2612 0.5008 <0.0001
Male (n = 80) 0.0308 0.1075 0.9617 0.9562 0.6667 <0.0001
(b) NHANES 2003–2004
Female(n = 712) 0.0667 0.0459 1.2241 1.2251 0.5027 <0.0001
Male(n = 787) 0.0699 0.0384 1.0768 1.0784 0.6042 <0.0001
(c) LPCH
Female(n = 1441) 0.0379 0.0372 1.4129 1.4129 0.3168 <0.0001
Male(n = 867) 0.0976 0.0396 1.1652 1.1687 0.5199 <0.0001
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excluded any biomarker electronically ﬂagged as abnormal by the
hospital electronic health record system. In reality, systems that
ﬂag are commonplace. Flagging of abnormal values is determined
by using reference ranges such that the likelihood of a biochemical
abnormality in a patient is small [29]. These reference ranges are
often computed as the mean plus or minus two standard devia-
tions of the normal sample population [30]. Individuals with multi-
ple time stamps associated with their biomarker measurements
had one chosen at random.
Data from LPCH consisted of 19,537 individuals aged between
12 and 18 associated with one or more of a set of 6416 ICD-9-
CM codes. There were a total of 3,585,609 measurements across
1936 biomarkers. Individuals not missing any biomarker measure-
ments required by their perspective models were retrieved and
used to predict age. The female population consisted of 1441 indi-
viduals and the male population consisted of 867 individuals. Our
model, when applied to the female population, resulted in a mean
error of 0.0379 years with a standard deviation of 1.4129 years
and an adjusted r2 of 0.3168. The application of our model to the
male population resulted in a mean error of 0.0976 years with a
standard deviation of 1.1652 years and an adjusted r2 of 0.5119
(Fig. 3c and Table 2c).
In order to assess the generalizability of our model to different
data sets we used Levene’s test to examine the homogeneity of
variance across samples [31]. One of the beneﬁts of Levene’s test
is that it does not require the underlying data to be normal. The
null-hypothesis of Levene’s test is that the population variances
are equal. We applied Levene’s test to determine whether the
differences between the predicted and actual age among the male
populations differ signiﬁcantly from one data set to another and
whether the differences between the predicted and actual age
among the female populations differ signiﬁcantly as well. The
male populations show no signiﬁcant differences across all three
datasets with a p-value cutoff of 0.05. The female populations
show no signiﬁcant differences across the datasets with the
exception of NHANES 2003–2004 and LPCH distributions. We also
applied the non-parametric K-sample Anderson–Darling test
(adk-test) [32]. The null-hypothesis of the adk-test is that K sam-
ples, which may be of differing sizes, come from a common con-
tinuous distribution. The adk-test recapitulated the results from
Levene’s test.
A random distribution for each gender group was created by
randomly sampling ages from the NHANES 2003–2004 dataset
and computing the error. Each dataset was compared to random
using Levene’s test as well as the adk-test and all were statistically
signiﬁcant (p-value < 0.05) (Fig. 4). This suggests that our model is
applicable to different data sets, including clinical data, and that
the errors generated are signiﬁcantly different that one would ex-
pect at random.3. Discussion
While it is often overlooked in traditional translational biomed-
ical informatics, where emphasis has focused around genes and
proteins and their relationships to clinical outcome, biomarker
data from electronic medical record systems are records of molec-
ular information that can also be related to physiological charac-
teristics, which include aging and disease status. Using publically
available data collected by the Centers for Disease Control and Pre-
vention in their biannual National Health and Nutrition Examina-
tion Survey (NHANES), we have proposed a set of physiological
measurements that change with age. We have demonstrated the
ability to estimate chronological age using these routinely-ob-
tained blood biomarkers for individuals between the ages of 12
and 18. Finally, we have been able to validate the gender-speciﬁc
models using an independent population gathered from the
NHANES 2003–2004 survey as well as clinical data from Lucile
Packard Children’s Hospital.
Our analysis has identiﬁed both known and potentially novel
biomarkers that are associated with age. Hematocrit and mean cell
volume have been previously shown to be correlated with age.
Daniel and colleagues showed that hematocrit levels in males in-
crease with age while remaining ﬂat in females [33]. This can be
attributed to a greater increase in size and volume of muscle ﬁbers
leading to a rise in hematocrit values. Our models seem to recapit-
ulate this. Whereas hematocrit is the third highest biomarker that
is informative for age prediction in males, it is the last in females.
Similarly, in the Bogalusa Heart Study, it was shown that mean cell
volume and age, in the age range of 12–17, had a signiﬁcant linear
trend in males that was absent in females [34]. Alkaline phospha-
tase originates mainly from the bone and liver [35]. The negative
coefﬁcients associated with alkaline phosphatase for both the
male and female subgroups indicate the steep decline in bone
growth known to occur after age 12. Bennet and colleagues have
shown that there is a relationship between serum alkaline phos-
phatase and sexual maturity rating and that serum alkaline phos-
phatase decreases after reaching peak height velocity of growth
[36]. Creatinine is a byproduct of the breakdown of muscle. It is
produced at a constant rate depending on the muscle mass of an
individual [35]. The positive sign of the coefﬁcients for both mod-
els reﬂects an increase in muscle mass that is expected as one
develops and has been observed in previous studies [37]. This
analysis has also been able to identify serum globulin as a poten-
tially novel factor that is predictive of female aging. It has been
previously shown that the gamma globulins IgA, IgG, and IgM in-
crease in normal individuals [38] but to our knowledge the total
serum globulin levels have never been associated with female
adolescent development. In addition to the biomarkers we used
for building our multivariate models, we have also provided an or-
dered list of biomarkers, many of which, to our knowledge, have
Fig. 4. Comparisons between the distribution of error between actual and predicted ages for NHANES 2001–2002, NHANES 2003–2004, LPCH, and random. Lower triangle
represents the CDF plot between the error distributions of the corresponding pairs. Upper triangle represents whether there is a signiﬁcant difference (p-value <0.05) between
the error distributions of the corresponding pairs using the Levene’s test and K-sample Anderson–Darling test. NS means not signiﬁcant. Left: female, right: male.
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investigation.
We acknowledge that a multivariate linear regression may not
be the optimal method to develop a predictive model due to the
non-linearity of clinical data. However, within our age range of
interest and due to our desire to develop the most parsimonious
solution, we believe that with slight data transformations, such
as the natural logarithm transformation for alkaline phosphatase,
we do not violate any of the requisites for the usage of linear
regressions. While Fliss has shown that artiﬁcial neural networks
perform better for age prediction when children and adults are
mixed [4], our population is very homogenous with ages ranging
from 12 to 18 and would expect comparable performance as was
exhibited when using increasingly homogenous age groups. The
use of linear models in such a manner also allows for features that
are more interpretable and which we can biologically pursue, in-
stead of the complex model ﬁt, such as in the case of an artiﬁcial
neural network, which may obfuscate what individual biomarkers
should be pursued biologically.
The models, when applied to LPCH had greater predictive error
due to factors including but not limited to the diagnostic status of
the individuals, the technical variance associated with medical
equipment and the lack of truly normal data. While we only exam-
ined normal values in clinical data which are based on clinical
guidelines, the majority of these individuals have an illness associ-
ated with them which may affect the biomarker value. The motiva-
tion for using only normal values was that it excluded the outliers
which are common in the hospital environment due to procedures
and/or effects of disease. Other methods of approaching this prob-
lem may involve quartile thresholding or applying a z-score
threshold.
While application of the models to LPCH data showed worse
performance compared to the NHANES data sets, we have shown
that the error distributions are not signiﬁcantly different with
one exception. This is noteworthy because both the populations
as well as the status of the individuals were different. The majorityof NHANES survey participants are healthy individuals. In contrast
to this, the majority of patients seen at LPCH have underlying phys-
iological conditions that may affect their biomarker measure-
ments. Regardless of this, the lack of signiﬁcant difference in
error distributions suggests that clinical data can be used to vali-
date models built using independent data sources.
The predictability of chronological age from the female cohort
in all data sets does worse than that of the male cohort. To our
knowledge, this is the ﬁrst time that this phenomenon has been
observed. An underlying physiological factor may account for this
discrepancy or it may be that the variance in females with regards
to age is greater than that of males. We also propose that the male
model is more likely to be directly applicable to male clinical pop-
ulations. The root mean squared error and r2 values change only
slightly between the application of the male model to both
NHANES and LPCH. The female model, however, shows a greater
magnitude of change when applied to NHANES and LPCH. This im-
plies that there is a physiological or condition speciﬁc occurrence
in the clinical setting that affects the applicability of the model.
We believe that this may be due to the nature of clinical data as
well as gender-speciﬁc features that may require further
investigation.
We show that models applied to cross-sectional cohort data can
be applied to the medical domain with a caveat that care must be
taken when applying the female model. Our analysis, in addition to
the work done by Fliss and colleagues, demonstrate that valuable
information can be gained when bioinformatics methods are di-
rectly applied to clinical data. Clinical biomarker data gathered
from electronic medical records offers investigators a new source
of information from which to better understand the underlying
biology. While we only examined chronological aging in this anal-
ysis, it is often the difference between the chronological age and
biological age that is indicative of a disease or condition. The ability
to computationally predict chronological age can help shed light on
these differences so that we can have a better understanding of
diseases that may modulate aging. For example, one can examine
364 D.P. Chen et al. / Journal of Biomedical Informatics 43 (2010) 358–364how disease affects the aging process by looking for perturbations
in the rate of aging among patient groups stratiﬁed by ICD-9-CM
codes [39]. While translational bioinformatics most often focuses
on taking knowledge gained from molecular data into the clinical
setting, reverse translational bioinformatics enables the use of clin-
ical data to shed light on physiological processes. We believe that
the vast amounts of clinical data from electronic medical records
should be leveraged for this purpose and that doing so will enable
pertinent physiological discoveries.
4. Conclusion
We have developed gender-speciﬁc models that predict pediat-
ric adolescent chronological age based on blood biomarker proﬁles.
The models resulted in previously known and possibly novel phys-
iological responses to pediatric aging. We have suggested that
models generated from biomarkers gathered from cross-sectional
surveys are applicable to other independent cohorts. Finally, we
have shown that clinical data can be used to validate these models.
We believe that these results imply that bioinformatics methods
can be applied directly to clinical data from electronic medical re-
cords to better understand biological processes underlying human
pathophysiology. The amount of clinical data is staggering and the
ability to leverage human data for reverse translational bioinfor-
matics will give greater insight into aging, diseases, and many
other dynamic human physiological processes.
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